Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pleural Neoplasms | 17 | 2022 | 607 | 3.480 |
Why?
|
Mesothelioma | 26 | 2022 | 818 | 3.420 |
Why?
|
Ubiquitin Thiolesterase | 3 | 2022 | 449 | 0.820 |
Why?
|
Asbestos | 2 | 2022 | 251 | 0.800 |
Why?
|
Lung Neoplasms | 12 | 2022 | 13102 | 0.610 |
Why?
|
Gene Expression Profiling | 8 | 2019 | 9438 | 0.430 |
Why?
|
Loss of Heterozygosity | 5 | 2001 | 684 | 0.410 |
Why?
|
Tumor Suppressor Proteins | 4 | 2022 | 2849 | 0.400 |
Why?
|
Biopsy, Fine-Needle | 2 | 2014 | 1094 | 0.340 |
Why?
|
Simian virus 40 | 3 | 2002 | 295 | 0.290 |
Why?
|
Gene Expression | 3 | 2020 | 7799 | 0.240 |
Why?
|
Chromosomes, Human, Pair 15 | 2 | 2001 | 373 | 0.220 |
Why?
|
Asbestosis | 1 | 2000 | 82 | 0.190 |
Why?
|
Chromosomes, Human, Pair 13 | 1 | 2000 | 197 | 0.180 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2000 | 299 | 0.170 |
Why?
|
Oligonucleotide Array Sequence Analysis | 4 | 2014 | 3920 | 0.150 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2013 | 602 | 0.150 |
Why?
|
Chromosome Deletion | 1 | 2001 | 1401 | 0.140 |
Why?
|
Lung | 2 | 2019 | 9856 | 0.140 |
Why?
|
Benzimidazoles | 1 | 2021 | 850 | 0.130 |
Why?
|
Paraffin Embedding | 1 | 2016 | 299 | 0.130 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2020 | 713 | 0.130 |
Why?
|
Tissue Fixation | 1 | 2016 | 241 | 0.130 |
Why?
|
Sp1 Transcription Factor | 1 | 2015 | 144 | 0.130 |
Why?
|
Formaldehyde | 1 | 2016 | 353 | 0.130 |
Why?
|
Pyrazines | 1 | 2021 | 1230 | 0.130 |
Why?
|
DNA Mutational Analysis | 2 | 2020 | 4186 | 0.120 |
Why?
|
Proto-Oncogene Proteins | 6 | 2021 | 4554 | 0.120 |
Why?
|
Immunotherapy, Adoptive | 1 | 2022 | 1270 | 0.120 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 1692 | 0.110 |
Why?
|
Killer Cells, Natural | 1 | 2022 | 2133 | 0.110 |
Why?
|
Prognosis | 4 | 2021 | 29063 | 0.110 |
Why?
|
Sensitivity and Specificity | 3 | 2014 | 14722 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-akt | 5 | 2008 | 2503 | 0.110 |
Why?
|
Cell Nucleus | 1 | 2020 | 2969 | 0.100 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 5221 | 0.100 |
Why?
|
Mutation | 5 | 2021 | 29786 | 0.100 |
Why?
|
RNA, Neoplasm | 2 | 2010 | 769 | 0.090 |
Why?
|
Tumor Cells, Cultured | 7 | 2005 | 6314 | 0.090 |
Why?
|
Cell Line, Tumor | 6 | 2022 | 16689 | 0.090 |
Why?
|
Humans | 39 | 2022 | 744343 | 0.090 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2020 | 8428 | 0.090 |
Why?
|
Monocytes | 1 | 2019 | 2596 | 0.090 |
Why?
|
Alternative Splicing | 2 | 2016 | 1117 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 2 | 2016 | 6538 | 0.080 |
Why?
|
Epithelial Cells | 1 | 2021 | 3690 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 4751 | 0.080 |
Why?
|
Immunohistochemistry | 3 | 2020 | 11366 | 0.080 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2016 | 1581 | 0.080 |
Why?
|
Dendritic Cells | 1 | 2019 | 2725 | 0.080 |
Why?
|
Membrane Proteins | 2 | 2022 | 7880 | 0.070 |
Why?
|
Neutrophils | 1 | 2019 | 3719 | 0.070 |
Why?
|
Rifabutin | 1 | 2006 | 52 | 0.070 |
Why?
|
Apoptosis Regulatory Proteins | 2 | 2008 | 1157 | 0.070 |
Why?
|
Apoptosis | 6 | 2015 | 9727 | 0.070 |
Why?
|
Cluster Analysis | 1 | 2013 | 2715 | 0.070 |
Why?
|
Proportional Hazards Models | 2 | 2016 | 12354 | 0.060 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2015 | 2948 | 0.060 |
Why?
|
Blotting, Southern | 2 | 2002 | 803 | 0.060 |
Why?
|
Macrophages | 1 | 2019 | 5655 | 0.060 |
Why?
|
Karyotyping | 2 | 2010 | 1243 | 0.060 |
Why?
|
Melanoma | 1 | 2022 | 5510 | 0.060 |
Why?
|
Cell Proliferation | 4 | 2020 | 10481 | 0.060 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2006 | 434 | 0.060 |
Why?
|
Aged, 80 and over | 2 | 2020 | 57776 | 0.060 |
Why?
|
Down-Regulation | 2 | 2008 | 3002 | 0.060 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12245 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2022 | 5686 | 0.050 |
Why?
|
Genes, ras | 1 | 2005 | 690 | 0.050 |
Why?
|
Microsatellite Repeats | 2 | 2001 | 802 | 0.050 |
Why?
|
Chromosomes, Artificial, Yeast | 1 | 2001 | 118 | 0.050 |
Why?
|
Young Adult | 2 | 2020 | 56430 | 0.050 |
Why?
|
Neoplasm Proteins | 2 | 2008 | 3703 | 0.050 |
Why?
|
Sex Factors | 1 | 2015 | 10397 | 0.050 |
Why?
|
Turkey | 1 | 2002 | 237 | 0.050 |
Why?
|
Alleles | 3 | 2001 | 6933 | 0.050 |
Why?
|
Situs Inversus | 1 | 2001 | 64 | 0.050 |
Why?
|
Genetic Testing | 1 | 2014 | 3444 | 0.050 |
Why?
|
Allelic Imbalance | 1 | 2001 | 77 | 0.050 |
Why?
|
Chromosome Mapping | 3 | 2010 | 4740 | 0.050 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2002 | 367 | 0.050 |
Why?
|
Protein Kinases | 2 | 2005 | 1640 | 0.050 |
Why?
|
Middle Aged | 4 | 2020 | 213383 | 0.050 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2021 | 3557 | 0.050 |
Why?
|
Repressor Proteins | 1 | 2011 | 3023 | 0.050 |
Why?
|
Embryonic Development | 1 | 2005 | 711 | 0.050 |
Why?
|
Adolescent | 2 | 2020 | 85781 | 0.050 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2001 | 380 | 0.040 |
Why?
|
Heparan Sulfate Proteoglycans | 1 | 2000 | 118 | 0.040 |
Why?
|
Chromosomes, Human, Pair 16 | 1 | 2001 | 354 | 0.040 |
Why?
|
Genetic Linkage | 2 | 2002 | 2421 | 0.040 |
Why?
|
CCAAT-Enhancer-Binding Proteins | 1 | 2020 | 286 | 0.040 |
Why?
|
Genes, bcl-2 | 1 | 1999 | 122 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 2 | 2000 | 1097 | 0.040 |
Why?
|
Heparitin Sulfate | 1 | 2000 | 225 | 0.040 |
Why?
|
Sequence Analysis, DNA | 1 | 2010 | 4803 | 0.040 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2005 | 851 | 0.040 |
Why?
|
Neurofibromatosis 2 | 1 | 2002 | 380 | 0.040 |
Why?
|
Paclitaxel | 1 | 2006 | 1708 | 0.040 |
Why?
|
Ovarian Neoplasms | 2 | 2006 | 4838 | 0.040 |
Why?
|
Female | 10 | 2020 | 380194 | 0.040 |
Why?
|
Male | 8 | 2020 | 350118 | 0.040 |
Why?
|
Reproducibility of Results | 2 | 2014 | 19905 | 0.040 |
Why?
|
DNA-Binding Proteins | 3 | 2011 | 9648 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2015 | 21746 | 0.040 |
Why?
|
Tumor Virus Infections | 1 | 2000 | 452 | 0.040 |
Why?
|
Deafness | 1 | 2002 | 458 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 12959 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2002 | 1434 | 0.040 |
Why?
|
Mice | 8 | 2021 | 81183 | 0.040 |
Why?
|
Epigenesis, Genetic | 2 | 2020 | 3647 | 0.040 |
Why?
|
Sequence Analysis, RNA | 2 | 2019 | 2012 | 0.040 |
Why?
|
Aged | 3 | 2020 | 163280 | 0.040 |
Why?
|
Telomerase | 1 | 2002 | 730 | 0.040 |
Why?
|
Genome, Human | 1 | 2010 | 4420 | 0.040 |
Why?
|
Proteoglycans | 1 | 2000 | 835 | 0.040 |
Why?
|
Ribonucleoprotein, U2 Small Nuclear | 1 | 2016 | 21 | 0.040 |
Why?
|
Body Patterning | 1 | 2001 | 626 | 0.040 |
Why?
|
Mice, Inbred NOD | 1 | 2021 | 1878 | 0.040 |
Why?
|
Peritoneal Neoplasms | 1 | 2002 | 665 | 0.030 |
Why?
|
Plicamycin | 1 | 2015 | 13 | 0.030 |
Why?
|
Gene Deletion | 2 | 2002 | 2751 | 0.030 |
Why?
|
Congenital Abnormalities | 1 | 2001 | 707 | 0.030 |
Why?
|
Adult | 4 | 2020 | 214055 | 0.030 |
Why?
|
Mice, SCID | 1 | 2021 | 2716 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2001 | 2649 | 0.030 |
Why?
|
Tumor Burden | 1 | 2021 | 1915 | 0.030 |
Why?
|
DNA, Viral | 1 | 2002 | 2225 | 0.030 |
Why?
|
Heterozygote | 1 | 2001 | 2804 | 0.030 |
Why?
|
Pneumonectomy | 1 | 2021 | 1094 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2022 | 1788 | 0.030 |
Why?
|
Phosphorylation | 4 | 2008 | 8436 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2008 | 2916 | 0.030 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 1999 | 859 | 0.030 |
Why?
|
Point Mutation | 2 | 2010 | 1623 | 0.030 |
Why?
|
Animals | 10 | 2021 | 168757 | 0.030 |
Why?
|
Enzyme Induction | 2 | 2005 | 475 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2002 | 6171 | 0.030 |
Why?
|
Phosphoric Monoester Hydrolases | 2 | 2005 | 431 | 0.030 |
Why?
|
Transcription Factors | 1 | 2011 | 12208 | 0.030 |
Why?
|
Models, Genetic | 1 | 2001 | 3494 | 0.020 |
Why?
|
Protein Isoforms | 1 | 2016 | 1730 | 0.020 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2020 | 1861 | 0.020 |
Why?
|
Lod Score | 2 | 2002 | 614 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 2001 | 4328 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 2183 | 0.020 |
Why?
|
DNA, Neoplasm | 2 | 2010 | 1758 | 0.020 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 2010 | 230 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2005 | 18029 | 0.020 |
Why?
|
Blotting, Western | 2 | 2011 | 5179 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2021 | 2727 | 0.020 |
Why?
|
bcl-2-Associated X Protein | 2 | 2002 | 295 | 0.020 |
Why?
|
Expressed Sequence Tags | 1 | 2009 | 255 | 0.020 |
Why?
|
INDEL Mutation | 1 | 2010 | 279 | 0.020 |
Why?
|
Hemodynamics | 1 | 1999 | 4199 | 0.020 |
Why?
|
Papillomavirus Infections | 1 | 2000 | 1587 | 0.020 |
Why?
|
RNA Precursors | 1 | 2009 | 208 | 0.020 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2011 | 893 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2001 | 2214 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2021 | 9734 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2015 | 13033 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2002 | 5021 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2011 | 1799 | 0.020 |
Why?
|
Nucleic Acid Hybridization | 2 | 2001 | 1375 | 0.020 |
Why?
|
Genes, Neoplasm | 1 | 2010 | 376 | 0.020 |
Why?
|
Computational Biology | 1 | 2020 | 3521 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3597 | 0.020 |
Why?
|
Cells, Cultured | 3 | 2011 | 19229 | 0.020 |
Why?
|
PTEN Phosphohydrolase | 2 | 2005 | 1142 | 0.020 |
Why?
|
Base Sequence | 1 | 2019 | 12797 | 0.020 |
Why?
|
Activin Receptors, Type I | 1 | 2008 | 142 | 0.020 |
Why?
|
Antigens, Nuclear | 1 | 2008 | 192 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2016 | 2440 | 0.020 |
Why?
|
KB Cells | 1 | 2006 | 14 | 0.020 |
Why?
|
RNA Editing | 1 | 2008 | 148 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2021 | 11031 | 0.020 |
Why?
|
Adenosine | 1 | 2011 | 825 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 1999 | 3670 | 0.020 |
Why?
|
Reference Standards | 1 | 2010 | 1025 | 0.020 |
Why?
|
Asbestos, Crocidolite | 1 | 2005 | 19 | 0.020 |
Why?
|
Myocardium | 1 | 1999 | 4776 | 0.020 |
Why?
|
Cocarcinogenesis | 1 | 2005 | 54 | 0.020 |
Why?
|
Tumor Suppressor Protein p14ARF | 1 | 2005 | 90 | 0.020 |
Why?
|
Genes, Neurofibromatosis 2 | 1 | 2005 | 124 | 0.020 |
Why?
|
Benzoquinones | 1 | 2006 | 201 | 0.020 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2005 | 2109 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 11524 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2001 | 4253 | 0.020 |
Why?
|
Mice, Nude | 1 | 2011 | 3689 | 0.020 |
Why?
|
Cell Adhesion | 1 | 2011 | 3144 | 0.020 |
Why?
|
Gene Rearrangement | 1 | 2010 | 1179 | 0.020 |
Why?
|
Chromones | 1 | 2004 | 154 | 0.020 |
Why?
|
Lactams, Macrocyclic | 1 | 2006 | 320 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2022 | 17446 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2002 | 6364 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 2002 | 5256 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2016 | 15519 | 0.010 |
Why?
|
Pedigree | 2 | 2002 | 4644 | 0.010 |
Why?
|
Chromosome Aberrations | 1 | 2010 | 1813 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2008 | 1526 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2004 | 2938 | 0.010 |
Why?
|
Genes, p53 | 1 | 2005 | 755 | 0.010 |
Why?
|
Carboplatin | 1 | 2006 | 801 | 0.010 |
Why?
|
Databases, Genetic | 1 | 2009 | 1783 | 0.010 |
Why?
|
HeLa Cells | 1 | 2008 | 3128 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2011 | 3505 | 0.010 |
Why?
|
Myosin Type II | 1 | 2002 | 68 | 0.010 |
Why?
|
Cystadenoma | 1 | 2002 | 84 | 0.010 |
Why?
|
Mice, Mutant Strains | 1 | 2005 | 1866 | 0.010 |
Why?
|
Gene Silencing | 1 | 2008 | 1538 | 0.010 |
Why?
|
Neurofibromin 2 | 1 | 2002 | 267 | 0.010 |
Why?
|
Morpholines | 1 | 2004 | 571 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2019 | 21827 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 1999 | 12072 | 0.010 |
Why?
|
Algorithms | 1 | 2021 | 13881 | 0.010 |
Why?
|
Quality of Life | 1 | 2022 | 12804 | 0.010 |
Why?
|
Transfection | 1 | 2008 | 5892 | 0.010 |
Why?
|
Cell Line, Transformed | 1 | 2002 | 898 | 0.010 |
Why?
|
Cell Death | 1 | 2006 | 1706 | 0.010 |
Why?
|
Myosin Heavy Chains | 1 | 2002 | 414 | 0.010 |
Why?
|
Glypicans | 1 | 2000 | 34 | 0.010 |
Why?
|
Cell Movement | 1 | 2011 | 5217 | 0.010 |
Why?
|
Polymorphism, Single-Stranded Conformational | 1 | 1999 | 335 | 0.010 |
Why?
|
Genes, Dominant | 1 | 2002 | 880 | 0.010 |
Why?
|
Rats, Inbred F344 | 1 | 2000 | 862 | 0.010 |
Why?
|
Rad51 Recombinase | 1 | 1999 | 189 | 0.010 |
Why?
|
Cisplatin | 1 | 2004 | 1662 | 0.010 |
Why?
|
In Situ Nick-End Labeling | 1 | 1999 | 643 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 13695 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2002 | 1850 | 0.010 |
Why?
|
Epithelium | 1 | 2002 | 1679 | 0.010 |
Why?
|
Sirolimus | 1 | 2004 | 1564 | 0.010 |
Why?
|
Cell Division | 1 | 2004 | 4568 | 0.010 |
Why?
|
DNA, Complementary | 1 | 2000 | 2050 | 0.010 |
Why?
|
Gene Dosage | 1 | 2001 | 1252 | 0.010 |
Why?
|
Family Health | 1 | 2001 | 1282 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 1999 | 2645 | 0.010 |
Why?
|
Enzyme Activation | 1 | 2002 | 3701 | 0.010 |
Why?
|
MicroRNAs | 1 | 2011 | 3752 | 0.010 |
Why?
|
Rats, Wistar | 1 | 1999 | 1901 | 0.010 |
Why?
|
Cell Survival | 1 | 2005 | 5882 | 0.010 |
Why?
|
Pancreas | 1 | 2002 | 1686 | 0.010 |
Why?
|
Haplotypes | 1 | 2001 | 2779 | 0.010 |
Why?
|
Risk Factors | 1 | 2021 | 72290 | 0.010 |
Why?
|
Signal Transduction | 2 | 2008 | 23403 | 0.010 |
Why?
|
United States | 1 | 2002 | 69872 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2006 | 10943 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2004 | 3798 | 0.010 |
Why?
|
Rats | 2 | 2000 | 24260 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2021 | 77449 | 0.010 |
Why?
|
Fibrosis | 1 | 1999 | 2029 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2002 | 2942 | 0.010 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2002 | 1634 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2005 | 14557 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2000 | 5867 | 0.000 |
Why?
|
DNA Methylation | 1 | 2000 | 4286 | 0.000 |
Why?
|
Cell Line | 1 | 2000 | 15997 | 0.000 |
Why?
|
Hypertension | 1 | 2005 | 8480 | 0.000 |
Why?
|
Heart Defects, Congenital | 1 | 2001 | 4584 | 0.000 |
Why?
|